Why the Immuron (ASX:IMC) share price is rocketing up 10% today

The Immuron Limited (ASX: IMC) share price is surging today following a research agreement with Monash University for combating COVID-19.

| More on:
A happy businessman pointing up, inidicating a rise in share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Immuron Ltd (ASX: IMC) share price is surging today following a research agreement with Monash University for combating COVID-19. At the time of writing, the Immuron share price is up 10.42% to 26.5 cents.

Immuron is clinical-stage biopharmaceutical company focused on the development and commercialisation of a novel class of specifically targeted polyclonal antibodies. The company researches and develops hyperimmune products for markets in Australia, the United States and Canada.

Product sales comprise Travelan and Protectyn, which is used for the prevention of travellers' diarrhoea.

What's pushing the Immuron share price higher?

The Immuron share price has been a positive mover today compared to the broader All Ordinaries Index (ASX: XAO) which is down 0.3% to 6.877 points.

According to today's release, Immuron advised that its hyperimmune bovine colostrum, called 'IMM-124E' has shown antiviral activity against COVID-19 in a laboratory. The hyperimmune bovine colostrum is used currently in the company's key products, Travelan and Protectyn.

To further support the promising results, Immuron has partnered with Monash University to undertake further research. The agreement will see Monash University examine and evaluate the efficacy of IMM-124E against the COVID-19 virus.

This follows the company's previous efforts in engaging with domestic and international researchers to advance its work.

What is hyperimmune bovine colostrum?

Bovine colostrum is a milky fluid that comes from the udder of cows the first few days after giving birth.

This fluid contains proteins called antibodies that can fight bacteria and viruses that cause diseases. Antibody levels in bovine colostrum can be 100 times higher than levels in regular cow's milk.

Researchers have created a special type of bovine colostrum called 'hyperimmune bovine colostrum'. It's produced by cows that have received vaccinations against specific disease-causing organisms and is high is specific kinds of antibodies.

Bovine colostrum is most commonly used to treat diarrhea and other infections.

What did the research team from Monash University say?

Microbiology Department deputy head, Professor Dena Lyras, said the university had been fortunate to obtain access to the SARS-CoV-2 recombinant proteins developed at the Peter Doherty Institute for Infection and Immunity.

Dr Melanie Hutton went on to talk about the research team's plan, saying:

These reagents will be used to initiate the research work and to develop a suitable assay for evaluating the inhibitory efficacy of IMM-124E.

Furthermore, specific immune components will be purified from IMM-124E and will be used to evaluate their ability to inhibit the binding of an antibody positive human serum sample to specific COVID-19 proteins, such as the spike protein which is crucial for cell entry.

Immuron share price summary

Investors are likely to have a mixed response to the Immuron share price. Although its shares have risen more than 85% in the past 12 months, short-term charts show the Immuron share price on a gradual decline.

The company's shares did see a sharp spike in July reaching 95 cents, following a market update to IMM-124E. However, the share price quickly came crashing down as investors pocketed the profit.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 shares can rise 20% to 50%

Let's see which shares are being tipped to rocket from current levels.

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors panicked when the latest inflation figures came out today.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Broker Notes

Why Guzman Y Gomez shares are a sell

Goldman Sachs has given its verdict on the burrito seller.

Read more »

A man pulls a shocked expression with mouth wide open as he holds up his laptop.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Mac Copper, Pro Medicus, Web Travel, and Yancoal shares are pushing higher today

These shares are having a good time on hump day. But why?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why ALS, Fisher & Paykel Healthcare, IPD, and Predictive Discovery shares are falling today

These shares are having a tough time on hump day. But why?

Read more »

Man looking at his grocery receipt, symbolising inflation.
Share Market News

How are ASX 200 investors responding to the latest Aussie inflation numbers?

The ASX 200 was up 0.2% today before the ABS reported the latest inflation figures.

Read more »

A couple makes silly chip moustache faces and take a selfie on their phone.
Broker Notes

Macquarie sees more upside in Telstra shares – What are they worth?

Telstra shares are up 34% over the past year, and Macquarie thinks there's more to come.

Read more »